Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
9.66
+0.16 (1.68%)
At close: Nov 22, 2024, 4:00 PM
9.88
+0.22 (2.28%)
After-hours: Nov 22, 2024, 4:19 PM EST
Amicus Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Amicus Therapeutics stock have an average target of 17.57, with a low estimate of 15 and a high estimate of 21. The average target predicts an increase of 81.88% from the current stock price of 9.66.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for FOLD stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $16 → $17 | Buy | Maintains | $16 → $17 | +75.98% | Nov 12, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $13 → $15 | Strong Buy | Maintains | $13 → $15 | +55.28% | Nov 7, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $20 → $21 | Buy | Maintains | $20 → $21 | +117.39% | Nov 7, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 7, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $13 → $15 | Strong Buy | Maintains | $13 → $15 | +55.28% | Oct 17, 2024 |
Financial Forecast
Revenue This Year
535.03M
from 399.36M
Increased by 33.97%
Revenue Next Year
651.33M
from 535.03M
Increased by 21.74%
EPS This Year
-0.21
from -0.51
EPS Next Year
0.20
from -0.21
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 554.3M | 717.1M | 928.0M | ||
| Avg | 535.0M | 651.3M | 816.5M | ||
| Low | 504.7M | 604.2M | 687.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 38.8% | 34.0% | 42.5% | ||
| Avg | 34.0% | 21.7% | 25.4% | ||
| Low | 26.4% | 12.9% | 5.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.11 | 0.32 | 0.80 | ||
| Avg | -0.21 | 0.20 | 0.57 | ||
| Low | -0.29 | 0.10 | 0.39 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 307.0% | ||
| Avg | - | - | 189.8% | ||
| Low | - | - | 99.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.